<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4506578</article-id><article-id pub-id-type="publisher-id">352</article-id><article-id pub-id-type="doi">10.1186/s12974-015-0352-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Evidence for the involvement of gamma delta T cells in the immune response in Rasmussen encephalitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Owens</surname><given-names>Geoffrey C.</given-names></name><address><email>geoffreyowens@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Erickson</surname><given-names>Kate L.</given-names></name><address><email>kerickson@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Malone</surname><given-names>Colin C.</given-names></name><address><email>ccmalone2014@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Calvin</given-names></name><address><email>calpan@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Huynh</surname><given-names>My N.</given-names></name><address><email>mhuynh@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Julia W.</given-names></name><address><email>jwchang@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Chirwa</surname><given-names>Thabiso</given-names></name><address><email>tchirwa@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Vinters</surname><given-names>Harry V.</given-names></name><address><email>HVinters@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Mathern</surname><given-names>Gary W.</given-names></name><address><email>gmathern@ucla.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff6"/><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Kruse</surname><given-names>Carol A.</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Department of Neurosurgery, David Geffen School of Medicine at University of California, Los Angeles, 300 Stein Plaza, Ste. 562, Los Angeles, CA 90095-6901 USA </aff><aff id="Aff2"><label/>Department of Human Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, USA </aff><aff id="Aff3"><label/>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA </aff><aff id="Aff4"><label/>Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA </aff><aff id="Aff5"><label/>Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA </aff><aff id="Aff6"><label/>Brain Research Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA </aff><aff id="Aff7"><label/>Mattel Children&#x02019;s Hospital, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>12</volume><elocation-id>134</elocation-id><history><date date-type="received"><day>17</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Owens et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Rasmussen encephalitis (RE) is a rare neuroinflammatory disease characterized by intractable seizures and progressive atrophy on one side of the cerebrum. Perivascular cuffing and clusters of T cells in the affected cortical hemisphere are indicative of an active cellular immune response.</p></sec><sec><title>Methods</title><p>Peripheral blood mononuclear cells (PBMCs) and brain-infiltrating lymphocytes (BILs) were isolated from 20 RE surgery specimens by standard methods, and CD3<sup>+</sup> T cell populations were analyzed by flow cytometry. Gamma delta T cell receptor spectratyping was carried out by nested PCR of reversed transcribed RNA extracted from RE brain tissue, followed by high resolution capillary electrophoresis. A MiSeq DNA sequencing platform was used to sequence the third complementarity determining region (CDR3) of &#x003b4;1 chains.</p></sec><sec><title>Results</title><p>CD3<sup>+</sup> BILs from all of the RE brain specimens comprised both &#x003b1;&#x003b2; and &#x003b3;&#x003b4; T cells. The median &#x003b1;&#x003b2;:&#x003b3;&#x003b4; ratio was 1.9 (range 0.58&#x02013;5.2) compared with a median ratio of 7.7 (range 2.7&#x02013;40.8) in peripheral blood from the same patients. The &#x003b1;&#x003b2; T cells isolated from brain tissue were predominantly CD8<sup>+</sup>, and the majority of &#x003b3;&#x003b4; T cells were CD4<sup>&#x02212;</sup> CD8<sup>&#x02212;</sup>. Staining for the early activation marker CD69 showed that a fraction of the &#x003b1;&#x003b2; and &#x003b3;&#x003b4; T cells in the BILs were activated (median 42&#x000a0;%; range 13&#x02013;91&#x000a0;%, and median 47&#x000a0;%; range 14&#x02013;99&#x000a0;%, respectively). Spectratyping T cell receptor (TCR) V&#x003b4;1-3 chains from 14 of the RE brain tissue specimens indicated that the &#x003b3;&#x003b4; T cell repertoire was relatively restricted. Sequencing &#x003b4;1 chain PCR fragments revealed that the same prevalent CDR3 sequences were found in all of the brain specimens. These CDR3 sequences were also detected in brain tissue from 15 focal cortical dysplasia (FCD) cases.</p></sec><sec><title>Conclusion</title><p>Neuroinflammation in RE involves both activated &#x003b1;&#x003b2; and &#x003b3;&#x003b4; T cells. The presence of &#x003b3;&#x003b4; T cells with identical TCR &#x003b4;1 chain CDR3 sequences in all of the brain specimens examined suggests that a non-major histocompatibility complex (MHC)-restricted immune response to the same antigen(s) is involved in the etiology of RE. The presence of the same &#x003b4;1 clones in CD brain implies the involvement of a common inflammatory pathway in both diseases.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12974-015-0352-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Rasmussen encephalitis</kwd><kwd>Brain</kwd><kwd>Inflammation</kwd><kwd>Focal cortical dysplasia</kwd><kwd>T cells</kwd><kwd>Gamma delta T cells</kwd><kwd>T cell receptor</kwd><kwd>CDR3</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Rasmussen encephalitis (RE) is a rare pediatric neurological disease with an estimated incidence in children under the age 18&#x000a0;years of 2&#x02013;3 per 10 million [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. The acute phase of the disease is characterized by intense uncontrolled partial or generalized seizures, and MRI FLAIR imaging often shows inflammation in one cerebral hemisphere [<xref ref-type="bibr" rid="CR3">3</xref>]. As the disease progresses, unilateral loss of cerebral tissue leaves the patient with severe hemiparesis and other neurological deficits. Corticosteroids may provide short term benefit but ultimately fail to halt the disease. Early treatment with tacrolimus or intravenous immunoglobulins may stabilize the neurological deterioration, but they do not reverse the intractable epilepsy [<xref ref-type="bibr" rid="CR2">2</xref>]. An inflammatory response involving T cells and activated microglia confined to the affected hemisphere appears to be the cause of the clinical symptoms. However, what precipitates the immune response is not known. Several types of Herpesviridae have been detected in surgical brain specimens from RE patients; however, to date, there is no consistent evidence for a pathogen that is common to all RE cases [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Likewise, autoantibodies have been described in RE cases indicative of an autoimmune disease, but autoantibodies have not been found in all RE cases [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>The observation of polarized granzyme B-containing CD8<sup>+</sup> T cells in brain parenchyma in close proximity to neurons and astrocytes has pointed to a role for major histocompatibility complex (MHC) class I-restricted CD8<sup>+</sup> cytotoxic T cells in RE [<xref ref-type="bibr" rid="CR12">12</xref>]. The cytotoxic T cells are likely reacting to foreign or self-antigens displayed by neurons and astrocytes in the affected cerebral hemisphere. Confinement of the T cells to one cerebral hemisphere suggests that the initial inflammatory reaction may have been spatially restricted. Such a reaction would have triggered a localized innate immune response by brain resident macrophages (microglia) and could have led to the recruitment of nonresident non-MHC-restricted immune cells, such as natural killer cells and &#x003b3;&#x003b4; T cells followed by primed MHC-restricted &#x003b1;&#x003b2; T cells. In the present study, we document for the first time the presence of clonally restricted &#x003b3;&#x003b4; T cells in brain tissue from RE patients, indicating a role for this T cell subtype in the inflammatory response in RE.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>RE patient cohort and clinical variables</title><p>Under the University of California, Los Angeles, Institutional Review Board (UCLA IRB) approval (IRB #11-00030), brain tissue and blood were collected at surgery as part of UCLA&#x02019;s Pediatric Epilepsy Surgery Program. For cases that were not treated at UCLA, tissue and blood were provided to UCLA under the auspices of the UCLA IRB approved Rare Brain Disease Tissue Bank (IRB# 13-001213). All of the patients or their parents or legal guardians provided informed consent for the use of the surgical remnant and blood for research purposes. All specimens were collected using the same standard operating procedures (SOPs); SOPs were provided by UCLA to the contributing institutions. De-identified patient information was collected with informed consent including age at seizure onset, age at surgery, gender, and affected cerebral hemisphere.</p></sec><sec id="Sec4"><title>Isolation of peripheral blood lymphocytes and brain-infiltrating lymphocytes</title><p>Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ). Brain-infiltrating lymphocytes (BILs) were isolated from collagenase-treated brain tissue by fractionation on a step gradient. Briefly, brain tissue was diced manually on ice in dissociation solution (HBSS with 20&#x000a0;mM HEPES pH 7.0, 5&#x000a0;mM glucose, and 50&#x000a0;U/ml penicillin/streptomycin). Tissue fragments were incubated with agitation in dissociation solution containing 0.5&#x000a0;mg/ml type IV collagenase (Worthington Biochemical Corp., Lakewood, NJ) and 5&#x000a0;% filtered human serum (Mediatech Inc., Manassas, VA) at 37&#x000a0;&#x000b0;C for 3&#x000a0;h or at room temperature overnight. The dissociated tissue was fractionated on a 30:70&#x000a0;% Percoll&#x000ae; (SigmaAldrich, St. Louis, MO) step gradient in RPMI containing 20&#x000a0;mM HEPES. PBMCs and BILs were cryopreserved in 90&#x000a0;% human serum/10&#x000a0;% DMSO.</p></sec><sec id="Sec5"><title>Analysis of lymphocytes by flow cytometry</title><p>Phenotypic data were acquired on an analytical LSRII flow cytometer (Becton Dickinson, San Jose, CA). The following antibodies were used: APC-efluor&#x000ae; 780-conjugated CD3 (clone UCHT1; eBioscience Inc., San Diego, CA), PE/Cy7-conjugated CD4 (clone SK3; eBioscience Inc.), PerCP/Cy5.5-conjugated CD8 (clone RPA-T8; eBioscience Inc.), APC-conjugated T cell receptor (TCR) &#x003b1;&#x003b2; (clone IP26; eBioscience Inc.), FITC-conjugated TCR &#x003b3;&#x003b4; (clone B1.1; eBioscience Inc.), PE-conjugated CD69 (clone FN50; eBioscience Inc.), PE-conjugated TCR V&#x003b4;2 (clone B6; Biolegend), and FITC-conjugated TCR V&#x003b4;1 (Clone TS8.2; GeneTex Inc., Irvine, CA). Data were analyzed with FlowJo software (TreeStar Inc., Ashland, OR); plots were exported to CorelDRAW X6 (Corel Corporation, Ottawa, Canada). Statistical analyses and graphing utilized R-project programs (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">www.r-project.org</ext-link>).</p></sec><sec id="Sec6"><title>Spectratyping T cell receptor V&#x003b4; chains</title><p>Total RNA was purified from flash frozen blocks of involved tissue consisting of mostly cortical gray matter (~50&#x000a0;mg) using Trizol&#x02122; (Life Technologies, Carlsbad, CA) followed by column purification (Qiagen, Valencia, CA). RNA was reverse transcribed (Qiagen), and PCR reactions were carried out in an Applied Biosystems (ABI) GeneAmp&#x000ae; PCR system 9700 using AccuPrime&#x02122; Taq polymerase (Life Technologies). The same primer sets described by Dechanet et al. [<xref ref-type="bibr" rid="CR13">13</xref>] were used; forward primers were unique to V&#x003b4;1, V&#x003b4;2, and V&#x003b4;3, respectively, and two nested reverse primers were located in the constant region. The sequences of each primer are as follows: V&#x003b4;1 5&#x02032; CTGTCAACTTCAAGAAAGCAGCGAAATC 3&#x02032;; V&#x003b4;2 5&#x02032; TACCGAGAAAAGGACATCTATGGC 3&#x02032;; V&#x003b4;3 5&#x02032;GGGGATAACAGCAGATCAGAAGGT 3&#x02032;; C&#x003b4;1.1 5&#x02032; TGGGAGAGATGCAATAGCAGGATC 3&#x02032;; C&#x003b4;1.2 5&#x02032; ACGGATGGTTTGGTAGAGGCTGA 3&#x02032;. The C&#x003b4;1.2 primer was end-labeled with 6-carboxyfluorescein (FAM). The cycling conditions were as follows: 94&#x000a0;&#x000b0;C 2&#x000a0;min followed by 40&#x000a0;cycles of 94&#x000a0;&#x000b0;C 45&#x000a0;s, 60&#x000a0;&#x000b0;C 45&#x000a0;s, 68&#x000a0;&#x000b0;C 45&#x000a0;s, and a run off step at 68&#x000a0;&#x000b0;C for 4&#x000a0;min. For the second round of PCR, the number of cycles was reduced to 35&#x000a0;cycles. FAM-labeled products were separated on an ABI 3730 Capillary DNA Analyzer (Life Technologies), and peak areas were calculated using ABI Peak Scanner Software 2 (Life Technologies). In order to compare the relative amounts of each V&#x003b4; chain-specific fragment between samples, areas of individual peaks in each sample were normalized to the total peak area in each sample. Data were clustered and displayed as a heat map using the GENE-E bioinformatics package (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/">www.broadinstitute.org</ext-link>).</p></sec><sec id="Sec7"><title>DNA sequencing T cell receptor V&#x003b4; CDR3s</title><p>First round V&#x003b4;2 and V&#x003b4;3 PCR fragments that yielded a single FAM-labeled fragment were re-amplified with the appropriate chain-specific forward primer and an unlabeled C&#x003b4;1.2 reverse primer. PCR products were treated with ExoSAP-IT (Affymetrix, Inc. Santa Clara, CA) and sequenced by the Sanger sequencing method using BigDye&#x000ae; cycle sequencing chemistry (Life Technologies). Sequences were analyzed using International Immunogenetics Information System (IMGT)/V-QUEST, the IMGT web portal for analysis of T cell receptor and immunoglobulin sequences [<xref ref-type="bibr" rid="CR14">14</xref>]. To sequence V&#x003b4;1 fragments, adaptors were added to the first round PCR products in the second PCR step, and the resulting DNA fragments were separated by agarose gel electrophoresis and purified (Qiagen). The following primers were used (TCR sequences are underlined): V&#x003b4;1 adaptor (forward primer) 5&#x02032; GAGACAGTCGTCGGCAGCGTCAGATGTATAACT<underline>GTCAACTTCAAGAAAGCAGGAAATC</underline> 3&#x02032;; C&#x003b4;1.2 adaptor (reverse primer) 5&#x02032; GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG<underline>ACGGATGGTTTGGTAGAGGCTGA</underline> 3&#x02032;. Nextera XT indices (Illumina, San Diego, CA) were added by tagging PCR using a KAPA Hifi PCR kit (KAPA Biosystems, Boston, MA), and the PCR products were purified using the Agencourt AMPure XP system (Beckman Coulter, Brea, CA). Fragments were sized on a Bioanalyzer instrument (Agilent Technologies, Inc. Santa Clara, CA), quantified by qPCR (KAPA library quant kit), and pooled. Libraries were sequenced on a MiSeq desktop sequencer using V2 2&#x02009;&#x000d7;&#x02009;250&#x000a0;bp chemistry (Illumina). IMGT/HighV-QUEST, the IMGT web portal for high throughput analysis of T cell receptor and immunoglobulin sequences was used to curate all of the sequence data [<xref ref-type="bibr" rid="CR14">14</xref>]. Scripts were written in R and Python to collate and enumerate the sequences. The &#x003b4;1-specific sequences from cortical dysplasia (CD) brain samples were generated as described above. In the second PCR step, CDR3 clone-specific forward primers were used together with an extended C&#x003b4;1.1 primer, 5&#x02032; CTGGGAGAGATGACAATAGCAGGATCAAACTCTG 3&#x02032;. The following forward primers were used: CDR3 ALGDSIPRRIAYTDKLI, 5&#x02032; GCTCTTGGGGATTCCATTCCTAGGAGGATAGCGTACACCGATAAACTCATC 3&#x02032;; CDR3 ALGGLGTGGYAYTDKLI, 5&#x02032; GCTCTTGGGGGGCTAGGTACTGGGGGATACGCCTACACCGATAAACTCATC 3&#x02032;; CDR3 ALGVPPRPSLYWGIGSLGSYTDKLI, 5&#x02032; GCTCTTGGGGTCCCGCCTCGACCTTCCCTCTACTGGGGGATAGGAAGCTTGGGCTCGTACACCGATAAACTCATC 3&#x02032;. The cycling conditions were as follows: 94&#x000a0;&#x000b0;C 2&#x000a0;min followed by 35&#x000a0;cycles of 94&#x000a0;&#x000b0;C 45&#x000a0;s, 68&#x000a0;&#x000b0;C 90&#x000a0;s, and a run off step at 68&#x000a0;&#x000b0;C for 4&#x000a0;min. PCR products were gel purified and sequenced by the Sanger sequencing method using BigDye&#x000ae; cycle sequencing chemistry (Life Technologies). Sequences were aligned in Seaview [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec8"><title>Immunocytochemistry</title><p>Surgical tissue blocks were fixed in freshly prepared 4&#x000a0;% paraformaldehyde in phosphate-buffered saline (PBS) for 24&#x02013;48&#x000a0;h, then cryoprotected by immersion overnight at 4&#x000a0;&#x000b0;C in 20&#x000a0;% sucrose-PBS followed by 30&#x000a0;% sucrose-PBS. Blocks were then frozen with powdered dry ice and stored at &#x02212;80&#x000a0;&#x000b0;C. Immunostaining was performed on free-floating 30-&#x003bc;m cryostat-cut sections by first blocking in PBS with 5&#x000a0;% normal goat serum (Vector Laboratories, Burlingame, CA) and 0.3&#x000a0;% Triton X-100 for 1&#x000a0;h. Sections were then incubated in mouse anti-human TCR pan &#x003b3;&#x003b4; (clone 5A6.E9, 1:100, Thermo Scientific, Waltham, MA) and an anti-human CD3 rabbit polyclonal antibody (1: 100, Dako North America, Inc. Carpinteria, CA) overnight at 4&#x000a0;&#x000b0;C followed by incubation in Alexa Fluor&#x000ae; 488 goat anti-rabbit and Alexa Fluor&#x000ae; 568 goat anti-mouse secondary antibodies (1:1000, Life Technologies) for 1&#x000a0;h at room temperature. Sections were mounted on slides and cover-slipped using ProLong&#x000ae; Gold anti-fade reagent containing DAPI (Life Technologies). Fluorescent images were acquired with an Olympus spinning disk confocal microscope (Olympus America, Inc., Center Valley, PA) controlled by SlideBook&#x02122; image acquisition and analysis software (Intelligent Imaging Innovations, Inc. Denver CO). Images were transferred to CorelDRAWX6 (Corel Corporation). Sections (5&#x000a0;&#x003bc;m) of paraffin-embedded involved tissue were deparaffinized and microwaved for 20&#x000a0;min in buffered citrate (10&#x000a0;mM, pH 6.0) to retrieve antigens. After blocking for 1&#x000a0;h (Impress Kit, Vector Laboratories, Burlingame, CA), sections were incubated overnight at 4&#x000a0;&#x000b0;C with rabbit anti-human CD3 (1:800, Dako) or mouse anti-human CD69 (clone CH11, 1:50, Abcam, Cambridge, MA). Peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (1: 300; Impress Kit, Vector Laboratories) were added for 1&#x000a0;h at room temperature, followed by incubation with 3,3&#x02032;-diaminobenzidine (DAB) substrate (MP Biomedicals, Santa Ana, CA) and subsequent counterstaining with hematoxylin. Omission of primary antibodies served as negative controls. Images of the entire sections were acquired with an Aperio ScanScope XT scanner (Aperio, Vista CA) and transferred to CorelDRAWX6 (Corel Corporation).</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>RE patient cohort and collection of surgical specimens</title><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> provides details of the RE patient cohort used in this study. There were no exclusion criteria. Blood was drawn from the arterial line prior to initiating the surgery. Brain tissue was placed into ice-cold Hibernate&#x000ae; medium immediately after resection. Samples of brain tissue and blood were sent to UCLA in shipping containers that kept the samples at 4&#x000a0;&#x000b0;C.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical data from 20 RE patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Case ID</th><th>Gender</th><th>Age at seizure onset (year)</th><th>Age at surgery (year)</th><th>Hemisphere</th></tr></thead><tbody><tr><td>RECP20</td><td>F</td><td>3</td><td>6.1</td><td>L</td></tr><tr><td>RECP21</td><td>M</td><td>8</td><td>11.9</td><td>L</td></tr><tr><td>RECP24</td><td>F</td><td>1.3</td><td>2.1</td><td>L</td></tr><tr><td>RECP25</td><td>M</td><td>8.3</td><td>14.9</td><td>L</td></tr><tr><td>RECP26</td><td>F</td><td>6</td><td>14.4</td><td>L</td></tr><tr><td>RECP27</td><td>F</td><td>7.8</td><td>8</td><td>R</td></tr><tr><td>RECP28</td><td>F</td><td>9</td><td>10</td><td>L</td></tr><tr><td>RECP29</td><td>M</td><td>10</td><td>13</td><td>R</td></tr><tr><td>RECP30</td><td>F</td><td>6</td><td>7.9</td><td>R</td></tr><tr><td>RECP31</td><td>M</td><td>6</td><td>9</td><td>R</td></tr><tr><td>RECP32</td><td>F</td><td>8</td><td>11</td><td>L</td></tr><tr><td>RECP33</td><td>M</td><td>4.3</td><td>5.8</td><td>L</td></tr><tr><td>RECP34</td><td>M</td><td>9</td><td>10.9</td><td>R</td></tr><tr><td>RECP35</td><td>F</td><td>4.5</td><td>6</td><td>L</td></tr><tr><td>RECP36</td><td>M</td><td>6</td><td>8</td><td>R</td></tr><tr><td>RECP37</td><td>F</td><td>3</td><td>3.3</td><td>R</td></tr><tr><td>RECP39</td><td>M</td><td>11</td><td>12</td><td>R</td></tr><tr><td>RECP42</td><td>F</td><td>3</td><td>4</td><td>L</td></tr><tr><td>RECP43</td><td>F</td><td>7</td><td>9.4</td><td>L</td></tr><tr><td>RECP46</td><td>F</td><td>6.2</td><td>6.7</td><td>L</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec11"><title>Brain-infiltrating CD3<sup>+</sup> cells are predominantly of CD8<sup>+</sup> &#x003b1;&#x003b2;<sup>+</sup> and CD4<sup>&#x02212;</sup> CD8<sup>&#x02212;</sup> &#x003b3;&#x003b4;<sup>+</sup> T cells</title><p>To isolate BILs, fresh surgical specimens were digested with collagenase and fractionated on Percoll&#x02122; step gradients. CD3<sup>+</sup> lymphocytes were compared with those in peripheral blood collected from the patients at the time of surgery. Cells were isolated and immunostained at different times because specimens were acquired over a period of 30&#x000a0;months. However, every effort was made to standardize all of the procedures. The yield of BILs varied between samples and was largely dependent upon the amount of tissue obtained.</p><p>BILs and PBMCs were gated on CD3, CD4, CD8, &#x003b1;&#x003b2;, and &#x003b3;&#x003b4; T cell markers. In each case, the percent of &#x003b1;&#x003b2; T cells was higher in the PBMC compared to the BIL fraction (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>); however, BILs contained significantly more &#x003b3;&#x003b4; T cells, which were mainly CD4<sup>&#x02212;</sup> CD8<sup>&#x02212;</sup> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). The median ratio of &#x003b1;&#x003b2;:&#x003b3;&#x003b4; T cells was 1.9 (range 0.58&#x02013;5.2) in the BIL fractions, compared with a median ratio of 7.7 (range 2.7&#x02013;40.8) in PBMCs (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). &#x003b1;&#x003b2; T cells were predominantly CD8<sup>+</sup> in the BIL populations, confirming previous immunocytochemical studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). The percentage of &#x003b3;&#x003b4; T cells in the BIL fractions was not significantly correlated with the age at which the patient presented with seizures, nor the length of time between seizure onset and surgery (<italic>p</italic>&#x02009;=&#x02009;0.7731 and <italic>p</italic>&#x02009;=&#x02009;0.1913, respectively).<fig id="Fig1"><label>Fig. 1</label><caption><p>Phenotypic analysis of CD3<sup>+</sup> T cell subsets in brain-infiltrating lymphocytes (BILs) and in peripheral blood mononuclear cells (PBMCs) from RE patients. The proportion of each T cell subtype as a percentage of the number of CD3<sup>+</sup> cells gated in each sample is shown. <bold>a</bold> Stacked dot plot showing the percent of &#x003b1;&#x003b2; T cells in BILs (<italic>red dots n</italic>&#x02009;=&#x02009;20) compared with PBMCs (<italic>blue dots</italic>) from the same cases (<italic>p</italic>&#x02009;=&#x02009;0.0001, pair-wise Wilcoxon signed-rank test). <bold>b</bold> Stacked dot plot showing the percent of TCR &#x003b3;&#x003b4; T cells in BILs compared with PBMCs from the same patients (<italic>p</italic>&#x02009;=&#x02009;0.0001, pair-wise Wilcoxon signed-rank test). <bold>c</bold> Stacked dot plot showing the ratio of CD4<sup>+</sup> &#x003b1;&#x003b2;:CD8<sup>+</sup> &#x003b1;&#x003b2; T cells in BILs compared with the corresponding PBMCs (<italic>p</italic>&#x02009;=&#x02009;0.0001, pair-wise Wilcoxon signed-rank test). <bold>d</bold> Plot of the percent of CD69+ &#x003b1;&#x003b2; T cells versus CD69+ &#x003b3;&#x003b4; T cells in BIL fractions (<italic>n</italic>&#x02009;=&#x02009;14; <italic>r</italic>&#x02009;=&#x02009;0.9547, CI 0.8595, 0.9859, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1 provides the quantitative data</p></caption><graphic xlink:href="12974_2015_352_Fig1_HTML" id="MO1"/></fig></p><p>Both &#x003b1;&#x003b2; and &#x003b3;&#x003b4; T cells in the BIL fractions analyzed (<italic>n</italic>&#x02009;=&#x02009;14) expressed the early activation marker CD69 indicating that an active immune reaction involving both T cell subtypes was taking place at the time of surgery in the affected cortical hemisphere of these patients. The percent of activated &#x003b1;&#x003b2; and &#x003b3;&#x003b4; T cells was highly correlated (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). CD69 expression by infiltrating T cells was confirmed by immunocytochemistry using a second CD69 antibody (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1).</p><p>Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows two examples of the distribution of &#x003b3;&#x003b4; T cells in involved cortical tissue. In Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a, b</xref>, perivascular T cells appear to be predominantly &#x003b3;&#x003b4; T cells, whereas in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d, e</xref>, &#x003b3;&#x003b4; T cells form only part of a large cluster of T cells within brain parenchyma. The other T cells in this cluster are likely to be CD8<sup>+</sup> &#x003b1;&#x003b2; T cells.<fig id="Fig2"><label>Fig. 2</label><caption><p>Identification of &#x003b3;&#x003b4; T cells in RE brain parenchyma by immunofluorescence microscopy. Sections of cortex from a RE hemispherectomy surgery were co-stained with a polyclonal CD3 antibody and a pan TCR &#x003b3;&#x003b4; mAb. CD3 staining was visualized with an Alexa Fluor&#x000ae; 568 secondary antibody (<bold>a</bold>. <bold>d</bold>), and TCR &#x003b3;&#x003b4; staining with an Alexa Fluor&#x000ae; 488 secondary antibody (<bold>b</bold>. <bold>e</bold>). <bold>c</bold>, <bold>f</bold> Merged images. <italic>Scale bars</italic> correspond to 100&#x000a0;&#x003bc;m</p></caption><graphic xlink:href="12974_2015_352_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>A restricted repertoire of &#x003b3;&#x003b4; T cells in RE brain tissue</title><p>To gain insight into the T cell receptor (TCR) repertoire of brain-infiltrating &#x003b3;&#x003b4; T cells, RNA was extracted from flash frozen brain tissue obtained from 14 of the 20 RE cases previously analyzed by flow cytometry. The RNA was transcribed into cDNA and was used as a template to amplify a sequence extending from within the variable regions of the three major TCR &#x003b4; genes (V&#x003b4;1, V&#x003b4;2, and V&#x003b4;3) to within the common constant region, thus spanning the third complementarity determining region (CDR3), a major determinant of &#x003b3;&#x003b4; TCR specificity [<xref ref-type="bibr" rid="CR19">19</xref>]. Fragment lengths differed due to variable D and J segment usage and nucleotide addition and trimming [<xref ref-type="bibr" rid="CR20">20</xref>]. The heat map in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> presents the results of the spectratyping where the different colors denote the relative amounts of each PCR product within a sample. Based on the number of fragments of different sizes, it appears that the repertoire of V&#x003b4; chains among the RE samples is relatively restricted. In several cases, only a single amplified product was obtained with the V&#x003b4;2- and V&#x003b4;3-specific primers (RECP25, RECP29, RECP31, RECP33 for V&#x003b4;2, and RECP26 for V&#x003b4;3) indicating the presence of single clones. These products were sequenced and, as expected from the size differences, encoded different CDR3 sequences (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S2). Compared to the number of V&#x003b4;1 fragments, there were fewer V&#x003b4;2- or V&#x003b4;3-specific products in each sample; several V&#x003b4;2 or V&#x003b4;3 fragments of the same size were found in over half of the samples. Four of the V&#x003b4;1 fragments (183, 186, 198, and 204&#x000a0;bp) were found in all of the samples, and a further three V&#x003b4;1 fragments (189, 195, and 201&#x000a0;bp) were found in 13/14 samples. One or more of these seven products were highly expressed in all of the samples, suggesting that they may represent the dominant V&#x003b4;1-containing &#x003b3;&#x003b4; T cell clones in these RE cases. Staining BILs from two of the RE cases (RECP26 and RECP33) with V&#x003b4;1- and V&#x003b4;2-specific antibodies showed that &#x02265;90&#x000a0;% of the &#x003b3;&#x003b4; T cells expressed V&#x003b4;1, suggesting that &#x003b4;1 clones may be highly represented in the populations of &#x003b3;&#x003b4; T cells in RE brain tissue. As expected, the corresponding PBMCs were &#x02265;77&#x000a0;% V&#x003b4;2<sup>+</sup> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR21">21</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><p>Heat map summarizing the spectratyping of V&#x003b4; chains in brain tissue from 14 RE patients. Sequences specific to the three major V&#x003b4; chains were amplified by nested PCR and separated by capillary electrophoresis. For each of the 14 RE samples and for each chain-specific primer, the area of each peak corresponding to a different fragment length was expressed as a fraction of the total area under the peaks and converted into a heat map. The data for each V&#x003b4; chain were clustered to show which samples were more related to each other based on the fragment lengths, which are listed above each heat map. RNA was extracted from samples of flash frozen brain tissue</p></caption><graphic xlink:href="12974_2015_352_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Expression of T cell receptor (TCR) V&#x003b4;1 and V&#x003b4;2 chains by &#x003b3;&#x003b4; T cells in brain-infiltrating lymphocytes (BILs) and peripheral blood mononuclear cells (PBMCs) from two RE patients. BILs and PBMCs from two RE cases were stained with CD3, CD4, CD8, TCR &#x003b1;&#x003b2;, TCR V&#x003b4;1-, and TCR V&#x003b4;2-specific antibodies. CD3<sup>+</sup> CD4<sup>&#x02212;</sup> CD8<sup>&#x02212;</sup> PBMCs are predominantly V&#x003b4;2<sup>+</sup> (76.7 and 79.8&#x000a0;% for RECP26 and RECP33, respectively), whereas most CD3<sup>+</sup> CD4<sup>&#x02212;</sup> CD8<sup>&#x02212;</sup> BILs express V&#x003b4;1 (89.8 and 97.1&#x000a0;% for RECP26 and RECP33, respectively). The number of CD3+ BILs gated was 1887 for RECP26 and 1516 for RECP33</p></caption><graphic xlink:href="12974_2015_352_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec13"><title>Identical V&#x003b4;1 CDR3 sequences in RE brain tissue</title><p>All of the V&#x003b4;1-specific PCR products were sequenced. DNA sequences were curated by submitting them to the IMGT/HighV-QEST web portal [<xref ref-type="bibr" rid="CR14">14</xref>]. Several thousand different &#x003b4;1 clonotypes were identified in each sample as defined by differences in the amino acids in the V gene segment that contribute to CDR3 (amino acids 105&#x02013;108 according to the IMGT standardized numbering system) and by D and J gene segment usage [<xref ref-type="bibr" rid="CR20">20</xref>]. Strikingly, less than 20 clonotypes were found at a frequency of &#x0003e;1&#x000a0;% in each sample, and these accounted for 64&#x02013;83&#x000a0;% of the clonotypes in each sample (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In order to tabulate the frequency of each clonotype in every sample and to determine the extent of overlap, a matrix was constructed for all of the clonotypes found at a frequency of &#x0003e;1&#x000a0;%. As shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> and in Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Table S3, 49 different clonotypes accounted for all of the clonotypes found at &#x0003e;1&#x000a0;% frequency in all of the samples. This indicates that there may be common antigenic targets recognized by these relatively abundant &#x003b3;&#x003b4; T cell clones. To obtain further evidence for this supposition, the CDR3 amino acid sequences of four dominant clonotypes (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> bold-faced type) were examined. Each clonotype comprised several thousand different CDR3 sequences as a result of nucleotide addition and trimming during somatic rearrangement of the TCR gene segments. For each of the four clonotypes, the most frequent CDR3 sequence in each sample was tabulated and compared. For three of the clonotypes, the same CDR3 sequences were found in all of the samples, albeit at varying frequencies (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>; Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Table S4). Strikingly, the most frequent CDR3 sequence in one of the clonotypes was the same in all of the samples (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>; Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Table S4). These CDR3 sequences were not found in a BLAST search of the IMGT database.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Evidence for a limited number of highly expressed &#x003b4;1 clonotypes in each RE brain specimen</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Case id</th><th>No. of clonotypes &#x0003e;1&#x000a0;%</th><th>Percent of total no. of clonotypes</th></tr></thead><tbody><tr><td>RECP20</td><td>12</td><td>79.1</td></tr><tr><td>RECP21</td><td>13</td><td>78.05</td></tr><tr><td>RECP24</td><td>16</td><td>80.31</td></tr><tr><td>RECP25</td><td>8</td><td>77.8</td></tr><tr><td>RECP26</td><td>9</td><td>83.39</td></tr><tr><td>RECP27</td><td>6</td><td>81.07</td></tr><tr><td>RECP28</td><td>9</td><td>78.87</td></tr><tr><td>RECP29</td><td>11</td><td>76.51</td></tr><tr><td>RECP30</td><td>14</td><td>77.67</td></tr><tr><td>RECP31</td><td>10</td><td>83.35</td></tr><tr><td>RECP32</td><td>6</td><td>83.17</td></tr><tr><td>RECP33</td><td>9</td><td>64.41</td></tr><tr><td>RECP34</td><td>15</td><td>72.05</td></tr><tr><td>RECP35</td><td>14</td><td>72.33</td></tr></tbody></table><table-wrap-foot><p>Sequences were assigned to individual clonotypes based on amino acid changes in the residues of the V gene segment that contribute to the CDR3 and D and J gene segment usage. The frequency of each clonotype was calculated. The number of clonotypes &#x0003e;1&#x000a0;% of the total were tabulated, and the frequencies of these clonotypes were summated to give the percentage of the total number of clonotypes</p></table-wrap-foot></table-wrap><fig id="Fig5"><label>Fig. 5</label><caption><p>Frequency of &#x003b4;1 clonotypes present at &#x0003e;1&#x000a0;% in RE brain tissue. PCR fragments amplified with a V&#x003b4;1-specific forward primer were sequenced on a MiSeq DNA sequencing platform. Sequences were assigned to individual T cell clonotypes based on three criteria: (1) nucleotides coding for the last four amino acids of the variable (<italic>V</italic>) region, which contribute to the third complementarity determining region (the IMGT algorithm lists amino acid changes with respect to a reference V&#x003b4;1 sequence, which is shown in the figure, (2) the number and identity of diversity (<italic>D</italic>) gene segments, and (3) the identity of the joining (<italic>J</italic>) gene sequences. There are three possible D gene segments and four possible J gene segments. Clonotypes were selected from each sample that comprised &#x0003e;1&#x000a0;% of the total repertoire in each sample. Collectively, these 49 clonotypes made up more than 70&#x000a0;% of the repertoire of &#x003b3;&#x003b4; T cells expressing V&#x003b4;1 in each of the RE brain tissue samples. Of these, several dominant clones were evident (<italic>bold-faced type</italic>). A heat map was generated from the quantitative data; the <italic>vertical columns</italic> show the relative abundance of each clonotype in each sample. The data are clustered to show which cases have the most similar repertoires. Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S3 shows the quantitative data</p></caption><graphic xlink:href="12974_2015_352_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Fig. 6</label><caption><p>Identical V&#x003b4;1 CDR3 sequences in dominant clonotypes present in RE brain tissue. CDR3 sequences of four dominant clonotypes were analyzed, and the most frequent CDR3 sequence in each sample was determined for each clonotype. Identical sequences were found in every sample for three of the clonotypes. The <italic>shaded amino acid</italic> is the last residue encoded in the V gene segment. A heat map was generated from the quantitative data; the <italic>rows</italic> show the relative abundance of each CDR3 sequence in each sample. Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Table S4 provides the quantitative data</p></caption><graphic xlink:href="12974_2015_352_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec14"><title>The identical &#x003b4;1 CDR3 sequences are detected in dysplastic cortical tissue</title><p>To determine whether the dominant &#x003b4;1 clones that we had identified were specific to RE, we designed CDR3 sequence specific PCR primers. We selected the three dominant clonotypes in which a single CDR3 amino sequence predominated (Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Table S4). DNA sequences were ranked according to their frequency of occurrence in each RE sample. For each CDR3, a PCR primer was synthesized based on the DNA sequence that was found at the highest frequency in the majority of the samples (Additional file <xref rid="MOESM6" ref-type="media">6</xref>: Table S5). We tested the primers on RNA extracted from brain specimens from 15 focal cortical dysplasia (FCD) type I surgical cases [<xref ref-type="bibr" rid="CR22">22</xref>] (Additional file <xref rid="MOESM7" ref-type="media">7</xref>: Table S6). Markers of inflammation, including T cells, have been previously detected in dysplastic brain tissue [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. With a median age at surgery of 10&#x000a0;years (range 0.8&#x02013;19 years), the FCD cases were in approximately the same age range as the RE cases (Additional file <xref rid="MOESM7" ref-type="media">7</xref>: Table S6). As summarized in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref> and Additional file <xref rid="MOESM8" ref-type="media">8</xref>: Figure S2, sequences identical to those found in the RE samples were detected, demonstrating that the &#x003b4;1 clones are not unique to RE.<fig id="Fig7"><label>Fig. 7</label><caption><p>V&#x003b4;1 CDR3 sequences in dominant clonotypes are detectable in resected cortical dysplasia brain tissue. Primers were designed based on the most prevalent DNA sequences that specified the CDR3 regions of three of the dominant &#x003b4;1 clonotypes identified in RE brain tissue. PCR products were sequenced. A <italic>red square</italic> denotes the presence of a sequence, and an <italic>open square</italic> indicates its absence. Aligned DNA sequences are shown in Additional file <xref rid="MOESM8" ref-type="media">8</xref>: Figure S2</p></caption><graphic xlink:href="12974_2015_352_Fig7_HTML" id="MO7"/></fig></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>With the participation of eleven other institutions, we accrued fresh brain specimens from 20 RE surgeries over a 2.5-year period. We have carried out an initial characterization of T cells isolated from these specimens in comparison with T cells in peripheral blood from the same patients. Several new and confirmatory observations were made. The profile of brain-infiltrating CD3<sup>+</sup> T cells was relatively consistent, comprising mostly CD8<sup>+</sup> &#x003b1;&#x003b2; and CD4<sup>&#x02212;</sup> CD8<sup>&#x02212;</sup> &#x003b3;&#x003b4; T cells with fewer CD4<sup>+</sup> &#x003b1;&#x003b2; T cells, whereas the profile of peripheral blood, collected at the time of surgery, was more variable. The predominance of CD8<sup>+</sup> T cells in the BIL populations agrees with published immunohistochemistry results [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>], but the presence of &#x003b3;&#x003b4; T cells is a new finding and has implications for the immune response in RE. This T cell subtype acts like an innate immune cell and plays an important role in both tumor and pathogen immune surveillance [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. &#x003b3;&#x003b4; T cells are mainly found in the skin, gut, lungs, and genitourinary tract and normally comprise only a small fraction of circulating T lymphocytes [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Unlike &#x003b1;&#x003b2; T cells, &#x003b3;&#x003b4; T cells recognize intact antigens and are not dependent on antigen presentation by classical MHC molecules [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. They recognize transformed and infected cells via NKG2D- and TCR-dependent binding [<xref ref-type="bibr" rid="CR29">29</xref>]. Stress-induced self-proteins related to MHC molecules, lipid moieties bound to CD1 proteins, heat shock proteins, and phosphorylated metabolites made by certain pathogens and tumor cells are recognized by &#x003b3;&#x003b4; T cells [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p>V&#x003b4; spectratyping showed that &#x003b3;&#x003b4; T cells in RE brain tissue were oligoclonal and revealed the presence of dominant clonotypes. V&#x003b2; spectratyping has also provided evidence for oligoclonality of &#x003b1;&#x003b2; T cells in RE [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Strikingly, the same CDR3 sequences in four abundant &#x003b4;1 clonotypes were highly represented in every sample. This finding strongly indicates that in all of the RE cases analyzed, and possibly in all RE cases, there are clones of &#x003b3;&#x003b4; T cells that recognize the same epitope(s). In a study of unrelated newborns who had been infected in utero with cytomegalovirus, T cells with identical TCR V&#x003b4;1 CDR3 sequences were found in the blood of every infected individual [<xref ref-type="bibr" rid="CR32">32</xref>]. It is thought that convergent recombination primarily accounts for the development of public T cell clones [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>The antigen(s) recognized by &#x003b3;&#x003b4; T cells in RE are currently unknown. As mentioned above, CD1 proteins are ligands for &#x003b3;&#x003b4; TCRs. The structures of two different &#x003b4;1 TCRs complexed with CD1d-bound sulfatide and CD1d-bound &#x003b1;-galactocerebroside, respectively, were recently determined [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Two CDR3 motifs, YWG and TDK, that were found to directly interact with residues in CD1d are present in several of the clones that we sequenced (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>), suggesting the possibility that some &#x003b3;&#x003b4; T cells in RE brain may bind CD1d. In addition, one of the prevalent CDR3 sequences that we identified contains the heptapeptide motif (AYTDKLI) that is also found in a &#x003b4;1-containing TCR that binds a stress regulated, MHC class I related molecule, MHC class I polypeptide related sequence A (MICA) [<xref ref-type="bibr" rid="CR36">36</xref>]. It should be possible to derive clonal lines of &#x003b3;&#x003b4; T cells from the RE BIL fractions and use binding assays to determine if they interact with these non-classical MHC class I molecules.</p><p>Using PCR primers designed to amplify the &#x003b4;1 CDR3 region from three of the dominant clones, we detected the same sequences in dysplastic brain tissue. The PCR detection method used was not quantitative; thus, we do not yet know how prevalent these &#x003b4;1 clones are in FCD brain. Further analysis of the &#x003b3;&#x003b4; T cell repertoire in FCD is clearly warranted and will be the subject of future studies. The finding of &#x003b3;&#x003b4; TCR sequences is not entirely unexpected as the presence of T cells in FCD brain has been reported [<xref ref-type="bibr" rid="CR23">23</xref>]. Finding the same &#x003b4;1 clones in RE and FCD is also consistent with reports of dual pathology [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. Whether the &#x003b3;&#x003b4; T cell clones that we have identified are only associated with inflammatory events in RE and FCD remains to be determined. If they can be detected in peripheral blood, then they might be useful as a diagnostic indicator of RE, FCD, or brain inflammation in general.</p><p>Both RE and FCD are associated with seizures, which have been shown to promote an inflammatory reaction in the brain [<xref ref-type="bibr" rid="CR43">43</xref>]. &#x003b3;&#x003b4; T cells are likely to be among the first immune cells to cross the blood brain barrier in response to pro-inflammatory cytokines such as IL-1&#x003b2; and IL-18 released by inflammasomes [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. The presence of inflammasomes associated with microglia in RE brain tissue has recently been described [<xref ref-type="bibr" rid="CR45">45</xref>]. In response to inflammatory cytokines, &#x003b3;&#x003b4; T cells can act as an innate immune cell and release inflammatory cytokines in particular IL-17 without TCR engagement potentially perpetuating an inflammatory reaction [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p>In RE, &#x003b3;&#x003b4; T cells may provide a link between inflammation in the brain and an adaptive immune response involving antigen-specific CD8<sup>+</sup> T cells. In multiple sclerosis plaques and psoriatic lesions, &#x003b3;&#x003b4; T cells are predominantly IL-17<sup>+</sup>, linking this functional subtype to autoimmunity [<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>]. On the other hand, they can act as an adaptive immune cell and bind a cognate antigen and produce IFN-&#x003b3; [<xref ref-type="bibr" rid="CR49">49</xref>]. Neurons and astrocytes that express specific stress-induced autoantigens might be directly engaged by Th1-polarized &#x003b3;&#x003b4; T cells. In mice, the costimulatory receptor CD27 is expressed by IFN-&#x003b3;<sup>+</sup> but not IL-17<sup>+</sup> &#x003b3;&#x003b4; T cells [<xref ref-type="bibr" rid="CR50">50</xref>]. Immunostaining BILs with CD27 antibodies may allow us to differentiate between these two functional types of &#x003b3;&#x003b4; T cells in RE brain tissue. Th1 cytokines such as IFN-&#x003b3; released by &#x003b3;&#x003b4; T cells would also be expected to promote a cytotoxic CD8<sup>+</sup> &#x003b1;&#x003b2; T cell response [<xref ref-type="bibr" rid="CR51">51</xref>]. IFN-&#x003b3; increases MHC class I on neurons, which would render them selectively vulnerable to CD8<sup>+</sup> cytotoxic &#x003b1;&#x003b2; T cells [<xref ref-type="bibr" rid="CR52">52</xref>]. &#x003b3;&#x003b4; T cells may also play an immunosuppressive role depending upon the stage of the disease, as appears be the case in multiple sclerosis [<xref ref-type="bibr" rid="CR47">47</xref>]. Multiple roles for &#x003b3;&#x003b4; T cells in RE might explain why the percentage of &#x003b3;&#x003b4; T cells in CD3<sup>+</sup> BILs isolated at the time of surgery appeared to be unrelated to the length of time between seizure onset and surgery.</p><p>The cause of RE is unknown. A role for predisposing genetic factors that would influence the outcome of an immune response resulting from seizure-induced inflammation has been proposed [<xref ref-type="bibr" rid="CR53">53</xref>]. An infectious agent may also be involved in the etiology of RE [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], which would fit with the known role of &#x003b3;&#x003b4; T cells in pathogen surveillance. In a separate RNAseq study, we have looked for evidence of a persistent viral infection in resected RE brain tissue but have not found any gene transcripts encoded by known viruses (unpublished results). In the absence of a persistent infection, RE could involve T cells that recognize an epitope common to both a foreign and a self-antigen, T cells that express dual receptors, or epitope spreading [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>].</p></sec><sec id="Sec16" sec-type="conclusion"><title>Conclusions</title><p>The cellular immune response in RE involves both classical &#x003b1;&#x003b2; T cells and non-classical &#x003b3;&#x003b4; T cells. The &#x003b3;&#x003b4; T cells appear to be clonally restricted, and prevalent clones may recognize a common antigen(s), possibly a self-antigen associated with stressed cells. &#x003b3;&#x003b4; T cells may facilitate the activation of auto-reactive &#x003b1;&#x003b2; T cells by releasing pro-inflammatory cytokines and promoting antigen presentation. The presence of the identical &#x003b4;1 subtype clones in CD brain implies the involvement of a common inflammatory pathway in both diseases.</p></sec></body><back><app-group><app id="App1"><sec id="Sec17"><title>Additional files</title><p><media position="anchor" xlink:href="12974_2015_352_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Phenotypes of T cells in BIL and PBMC populations from individual RE patients.</p></caption></media><media position="anchor" xlink:href="12974_2015_352_MOESM2_ESM.pdf" id="MOESM2"><label>Additional file 2: Figure S1.</label><caption><p>CD69 expression by T cells in resected RE brain tissue. Sections of cortex from three RE surgery cases (A, B RECP27; C, D RECP34; D, E RECP37) were stained with either a CD3 polyclonal antibody (A, C, E) or a CD69 mAb (B, D, F). Clusters of T cells, identified by CD3 immunostaining, contain CD69-positive cells. Insets show higher magnification of cells in the upper clusters in each panel (arrows). Scale bars correspond to 200 and 25&#x000a0;micrometers (insets).</p></caption></media><media position="anchor" xlink:href="12974_2015_352_MOESM3_ESM.docx" id="MOESM3"><label>Additional file 3: Table S2.</label><caption><p>CDR3 sequences of V&#x003b4;2 and V&#x003b4;3 clones unique to individual RE cases.</p></caption></media><media position="anchor" xlink:href="12974_2015_352_MOESM4_ESM.docx" id="MOESM4"><label>Additional file 4: Table S3.</label><caption><p>Frequency of overlapping clonotypes in each sample as a percentage of the total number of clonotypes in each sample.</p></caption></media><media position="anchor" xlink:href="12974_2015_352_MOESM5_ESM.docx" id="MOESM5"><label>Additional file 5: Table S4.</label><caption><p>Frequency of identical CDR3 sequences for dominant clonotypes found in every sample.</p></caption></media><media position="anchor" xlink:href="12974_2015_352_MOESM6_ESM.docx" id="MOESM6"><label>Additional file 6: Table S5.</label><caption><p>Frequency of identical CDR3 DNA sequences for dominant clonotypes found in every sample.</p></caption></media><media position="anchor" xlink:href="12974_2015_352_MOESM7_ESM.docx" id="MOESM7"><label>Additional file 7: Table S6.</label><caption><p>Clinical data from 15 Focal cortical dysplasia patients.</p></caption></media><media position="anchor" xlink:href="12974_2015_352_MOESM8_ESM.docx" id="MOESM8"><label>Additional file 8: Figure S2.</label><caption><p>Alignment of clone-specific CDR3 sequences from FCD cases.</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>BILs</term><def><p>brain-infiltrating lymphocytes</p></def></def-item><def-item><term>CDR3</term><def><p>third complementarity determining region</p></def></def-item><def-item><term>FCD</term><def><p>focal cortical dysplasia</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p>interferon-gamma</p></def></def-item><def-item><term>MHC</term><def><p>major histocompatibility complex</p></def></def-item><def-item><term>MICA</term><def><p>MHC class I polypeptide related sequence A</p></def></def-item><def-item><term>PBMCs</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>RE</term><def><p>Rasmussen encephalitis</p></def></def-item><def-item><term>TCR</term><def><p>T cell receptor</p></def></def-item></def-list></glossary><fn-group><fn><p>Author Carol A. Kruse deceased.</p></fn><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>GCO designed the study, performed PCRs, analyzed the data, and drafted the manuscript; KLE prepared PBMCs and carried out flow cytometry; CCM prepared BILs and carried out flow cytometry; CP performed the bioinformatics analysis; MH prepared BILs and carried out immunocytochemistry; JWC prepared BILs and PBMCs; TC coordinated acquisition of RE specimens; HVV provided tissue sections and helped draft the manuscript; GWM provided surgical specimens and helped draft the manuscript; CAK helped design the study and draft the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are indebted to the following investigators for providing specimens from RE surgeries: Drs. Carlos Pardo and Adam Hartman (Johns Hopkins School of Medicine, Baltimore, MD); Drs. William Gaillard and Judy Liu (Children&#x02019;s National Medical Center, Washington, DC); Drs. Sookyong Koh and Douglas Nordli (Northwestern University Feinberg School of Medicine, Chicago IL); Dr. Brent O&#x02019;Neill (University of Colorado School of Medicine); Dr. Gerald Grant (Stanford University School of Medicine); Drs. Tiziana Granata and Elena Freri (Instituto Neurologico Carlo Besta, Milan, Italy); Dr. Alexandre Rainha Campos (CUF Descobertas Hospital, Lisbon, Portugal); Dr. Stephen Malone and Alex Micati (Children&#x02019;s Hospital at Westmead, Australia); Drs. Tonicarlo Velasco and Helio Marcado (Hospital das Cl&#x000ed;nicas da Faculdade de Medicina de Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o Paulo); Dr. Matt Wheatley (University of Alberta School of Medicine, Edmonton, Canada); and Dr. Amanda Yaun, (University of Oklahoma College of Medicine, Oklahoma City, OK). The Rasmussen Encephalitis Consortium contributes to the tissue transfer program, which is supported by the RE Children&#x02019;s Project (<ext-link ext-link-type="uri" xlink:href="http://www.rechildrens.org">www.REchildrens.org</ext-link>). We would also like to thank Sugandha Dandekar and Hemani Wijesuriya, UCLA GenoSeq Core Laboratory for spectratyping and DNA sequencing. Financial support was provided by the RE Children&#x02019;s Project (CAK/GWM/GCO), NIH R01 NS083823 (GWM), NIH R01CA125244 (CAK), R01CA154256 (CAK), and the University of California Pediatric Neuropathology Consortium (HVV).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>T</given-names></name><name><surname>Olszewski</surname><given-names>J</given-names></name><name><surname>Lloydsmith</surname><given-names>D</given-names></name></person-group><article-title>Focal seizures due to chronic localized encephalitis</article-title><source>Neurology</source><year>1958</year><volume>8</volume><fpage>435</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1212/WNL.8.6.435</pub-id><?supplied-pmid 13566382?><pub-id pub-id-type="pmid">13566382</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bien</surname><given-names>CG</given-names></name><name><surname>Tiemeier</surname><given-names>H</given-names></name><name><surname>Sassen</surname><given-names>R</given-names></name><name><surname>Kuczaty</surname><given-names>S</given-names></name><name><surname>Urbach</surname><given-names>H</given-names></name><etal/></person-group><article-title>Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins</article-title><source>Epilepsia</source><year>2013</year><volume>54</volume><fpage>543</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1111/epi.12042</pub-id><?supplied-pmid 23216622?><pub-id pub-id-type="pmid">23216622</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadkar</surname><given-names>S</given-names></name><name><surname>Bien</surname><given-names>CG</given-names></name><name><surname>Kruse</surname><given-names>CA</given-names></name><name><surname>Jensen</surname><given-names>FE</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Rasmussen&#x02019;s encephalitis: clinical features, pathobiology, and treatment advances</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70260-6</pub-id><?supplied-pmid 24457189?><pub-id pub-id-type="pmid">24457189</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>GF</given-names></name><name><surname>Renella</surname><given-names>RR</given-names></name></person-group><article-title>Epstein-Barr virus in brain and Rasmussen&#x02019;s encephalitis</article-title><source>Lancet</source><year>1989</year><volume>1</volume><fpage>279</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(89)91292-0</pub-id><?supplied-pmid 2563444?><pub-id pub-id-type="pmid">2563444</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Poland</surname><given-names>SD</given-names></name><name><surname>Blume</surname><given-names>WT</given-names></name><name><surname>Girvin</surname><given-names>JP</given-names></name><name><surname>Rice</surname><given-names>GP</given-names></name></person-group><article-title>Cytomegalovirus and Rasmussen&#x02019;s encephalitis</article-title><source>Lancet</source><year>1990</year><volume>336</volume><fpage>1282</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(90)92965-K</pub-id><?supplied-pmid 1978116?><pub-id pub-id-type="pmid">1978116</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Wiley</surname><given-names>CA</given-names></name></person-group><article-title>Herpesviruses in chronic encephalitis associated with intractable childhood epilepsy</article-title><source>Hum Pathol</source><year>1993</year><volume>24</volume><fpage>871</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/0046-8177(93)90137-6</pub-id><?supplied-pmid 8397159?><pub-id pub-id-type="pmid">8397159</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>MR</given-names></name><name><surname>Terrell</surname><given-names>W</given-names></name><name><surname>Hulette</surname><given-names>CM</given-names></name></person-group><article-title>Rasmussen&#x02019;s syndrome: a study of potential viral etiology</article-title><source>Clin Neuropathol</source><year>1995</year><volume>14</volume><fpage>7</fpage><lpage>12</lpage><?supplied-pmid 7729084?><pub-id pub-id-type="pmid">7729084</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>SW</given-names></name><name><surname>Andrews</surname><given-names>PI</given-names></name><name><surname>Gahring</surname><given-names>LC</given-names></name><name><surname>Whisenand</surname><given-names>T</given-names></name><name><surname>Cauley</surname><given-names>K</given-names></name><etal/></person-group><article-title>Autoantibodies to glutamate receptor GluR3 in Rasmussen&#x02019;s encephalitis</article-title><source>Science</source><year>1994</year><volume>265</volume><fpage>648</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1126/science.8036512</pub-id><?supplied-pmid 8036512?><pub-id pub-id-type="pmid">8036512</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiendl</surname><given-names>H</given-names></name><name><surname>Bien</surname><given-names>CG</given-names></name><name><surname>Bernasconi</surname><given-names>P</given-names></name><name><surname>Fleckenstein</surname><given-names>B</given-names></name><name><surname>Elger</surname><given-names>CE</given-names></name><etal/></person-group><article-title>GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen&#x02019;s encephalitis</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>1511</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1212/WNL.57.8.1511</pub-id><?supplied-pmid 11673604?><pub-id pub-id-type="pmid">11673604</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Bermudez</surname><given-names>I</given-names></name><name><surname>Houlihan</surname><given-names>L</given-names></name><name><surname>Clover</surname><given-names>L</given-names></name><etal/></person-group><article-title>Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000132651.66689.0F</pub-id><?supplied-pmid 15249609?><pub-id pub-id-type="pmid">15249609</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantegazza</surname><given-names>R</given-names></name><name><surname>Bernasconi</surname><given-names>P</given-names></name><name><surname>Baggi</surname><given-names>F</given-names></name><name><surname>Spreafico</surname><given-names>R</given-names></name><name><surname>Ragona</surname><given-names>F</given-names></name><etal/></person-group><article-title>Antibodies against GluR3 peptides are not specific for Rasmussen&#x02019;s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures</article-title><source>J Neuroimmunol</source><year>2002</year><volume>131</volume><fpage>179</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(02)00261-8</pub-id><?supplied-pmid 12458050?><pub-id pub-id-type="pmid">12458050</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bien</surname><given-names>CG</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Deckwerth</surname><given-names>TL</given-names></name><name><surname>Wiendl</surname><given-names>H</given-names></name><name><surname>Deckert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen&#x02019;s encephalitis</article-title><source>Ann Neurol</source><year>2002</year><volume>51</volume><fpage>311</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/ana.10100</pub-id><?supplied-pmid 11891826?><pub-id pub-id-type="pmid">11891826</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dechanet</surname><given-names>J</given-names></name><name><surname>Merville</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>Retiere</surname><given-names>C</given-names></name><name><surname>Pitard</surname><given-names>V</given-names></name><etal/></person-group><article-title>Implication of gammadelta T cells in the human immune response to cytomegalovirus</article-title><source>J Clin Invest</source><year>1999</year><volume>103</volume><fpage>1437</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1172/JCI5409</pub-id><?supplied-pmid 10330426?><pub-id pub-id-type="pmid">10330426</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamyar</surname><given-names>E</given-names></name><name><surname>Duroux</surname><given-names>P</given-names></name><name><surname>Lefranc</surname><given-names>MP</given-names></name><name><surname>Giudicelli</surname><given-names>V</given-names></name></person-group><article-title>IMGT((R)) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS</article-title><source>Methods Mol Biol</source><year>2012</year><volume>882</volume><fpage>569</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-842-9_32</pub-id><?supplied-pmid 22665256?><pub-id pub-id-type="pmid">22665256</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouy</surname><given-names>M</given-names></name><name><surname>Guindon</surname><given-names>S</given-names></name><name><surname>Gascuel</surname><given-names>O</given-names></name></person-group><article-title>SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building</article-title><source>Mol Biol Evol</source><year>2010</year><volume>27</volume><fpage>221</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/molbev/msp259</pub-id><?supplied-pmid 19854763?><pub-id pub-id-type="pmid">19854763</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prayson</surname><given-names>RA</given-names></name><name><surname>Frater</surname><given-names>JL</given-names></name></person-group><article-title>Rasmussen encephalitis: a clinicopathologic and immunohistochemical study of seven patients</article-title><source>Am J Clin Pathol</source><year>2002</year><volume>117</volume><fpage>776</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1309/AD8R-560C-4V11-C5E2</pub-id><?supplied-pmid 12090428?><pub-id pub-id-type="pmid">12090428</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>CA</given-names></name><name><surname>Vining</surname><given-names>EP</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Skolasky</surname><given-names>RL</given-names></name><name><surname>Carson</surname><given-names>BS</given-names></name><etal/></person-group><article-title>The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies</article-title><source>Epilepsia</source><year>2004</year><volume>45</volume><fpage>516</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.33103.x</pub-id><?supplied-pmid 15101833?><pub-id pub-id-type="pmid">15101833</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>GC</given-names></name><name><surname>Huynh</surname><given-names>MN</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>McArthur</surname><given-names>DL</given-names></name><name><surname>Hickey</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Differential expression of interferon-gamma and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response</article-title><source>J Neuroinflammation</source><year>2013</year><volume>10</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-10-56</pub-id><?supplied-pmid 23639073?><pub-id pub-id-type="pmid">23639073</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Born</surname><given-names>WK</given-names></name><name><surname>Kemal Aydintug</surname><given-names>M</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>RL</given-names></name></person-group><article-title>Diversity of gammadelta T-cell antigens</article-title><source>Cell Mol Immunol</source><year>2013</year><volume>10</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/cmi.2012.45</pub-id><?supplied-pmid 23085946?><pub-id pub-id-type="pmid">23085946</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayday</surname><given-names>AC</given-names></name></person-group><article-title>[Gamma][delta] cells: a right time and a right place for a conserved third way of protection</article-title><source>Annu Rev Immunol</source><year>2000</year><volume>18</volume><fpage>975</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.18.1.975</pub-id><?supplied-pmid 10837080?><pub-id pub-id-type="pmid">10837080</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>DJ</given-names></name><name><surname>Neves</surname><given-names>JF</given-names></name><name><surname>Sumaria</surname><given-names>N</given-names></name><name><surname>Pennington</surname><given-names>DJ</given-names></name></person-group><article-title>Understanding the complexity of gammadelta T-cell subsets in mouse and human</article-title><source>Immunology</source><year>2012</year><volume>136</volume><fpage>283</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2012.03582.x</pub-id><?supplied-pmid 22385416?><pub-id pub-id-type="pmid">22385416</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumcke</surname><given-names>I</given-names></name><name><surname>Thom</surname><given-names>M</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name><name><surname>Armstrong</surname><given-names>DD</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><etal/></person-group><article-title>The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission</article-title><source>Epilepsia</source><year>2011</year><volume>52</volume><fpage>158</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02777.x</pub-id><?supplied-pmid 21219302?><pub-id pub-id-type="pmid">21219302</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>A</given-names></name><name><surname>Zurolo</surname><given-names>E</given-names></name><name><surname>Spliet</surname><given-names>WG</given-names></name><name><surname>van Rijen</surname><given-names>PC</given-names></name><name><surname>Baayen</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias</article-title><source>Epilepsia</source><year>2010</year><volume>51</volume><fpage>1763</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02547.x</pub-id><?supplied-pmid 20345941?><pub-id pub-id-type="pmid">20345941</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayday</surname><given-names>AC</given-names></name></person-group><article-title>Gammadelta T cells and the lymphoid stress-surveillance response</article-title><source>Immunity</source><year>2009</year><volume>31</volume><fpage>184</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.006</pub-id><?supplied-pmid 19699170?><pub-id pub-id-type="pmid">19699170</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabelitz</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name><name><surname>Wesch</surname><given-names>D</given-names></name><name><surname>Oberg</surname><given-names>HH</given-names></name></person-group><article-title>Regulatory functions of gammadelta T cells</article-title><source>Int Immunopharmacol</source><year>2013</year><volume>16</volume><fpage>382</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2013.01.022</pub-id><?supplied-pmid 23481270?><pub-id pub-id-type="pmid">23481270</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girardi</surname><given-names>M</given-names></name></person-group><article-title>Immunosurveillance and immunoregulation by gammadelta T cells</article-title><source>J Invest Dermatol</source><year>2006</year><volume>126</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700003</pub-id><?supplied-pmid 16417214?><pub-id pub-id-type="pmid">16417214</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalyan</surname><given-names>S</given-names></name><name><surname>Kabelitz</surname><given-names>D</given-names></name></person-group><article-title>Defining the nature of human gammadelta T cells: a biographical sketch of the highly empathetic</article-title><source>Cell Mol Immunol</source><year>2013</year><volume>10</volume><fpage>21</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/cmi.2012.44</pub-id><?supplied-pmid 23085947?><pub-id pub-id-type="pmid">23085947</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>YH</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Bonneville</surname><given-names>M</given-names></name></person-group><article-title>gammadelta T cells: first line of defense and beyond</article-title><source>Annu Rev Immunol</source><year>2014</year><volume>32</volume><fpage>121</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120216</pub-id><?supplied-pmid 24387714?><pub-id pub-id-type="pmid">24387714</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribot</surname><given-names>JC</given-names></name><name><surname>debarros</surname><given-names>A</given-names></name><name><surname>Silva-Santos</surname><given-names>B</given-names></name></person-group><article-title>Searching for &#x0201c;signal 2&#x0201d;: costimulation requirements of gammadelta T cells</article-title><source>Cell Mol Life Sci</source><year>2011</year><volume>68</volume><fpage>2345</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1007/s00018-011-0698-2</pub-id><?supplied-pmid 21541698?><pub-id pub-id-type="pmid">21541698</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>N</given-names></name><name><surname>Bien</surname><given-names>CG</given-names></name><name><surname>Waschbisch</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Vince</surname><given-names>GH</given-names></name><etal/></person-group><article-title>CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery</article-title><source>Brain</source><year>2009</year><volume>132</volume><fpage>1236</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1093/brain/awp003</pub-id><?supplied-pmid 19179379?><pub-id pub-id-type="pmid">19179379</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Uccelli</surname><given-names>A</given-names></name><name><surname>Laxer</surname><given-names>KD</given-names></name><name><surname>Jeong</surname><given-names>MC</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><etal/></person-group><article-title>Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>1428</fpage><lpage>37</lpage><?supplied-pmid 9013988?><pub-id pub-id-type="pmid">9013988</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermijlen</surname><given-names>D</given-names></name><name><surname>Brouwer</surname><given-names>M</given-names></name><name><surname>Donner</surname><given-names>C</given-names></name><name><surname>Liesnard</surname><given-names>C</given-names></name><name><surname>Tackoen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human cytomegalovirus elicits fetal gammadelta T cell responses in utero</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><fpage>807</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1084/jem.20090348</pub-id><?supplied-pmid 20368575?><pub-id pub-id-type="pmid">20368575</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturi</surname><given-names>V</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Davenport</surname><given-names>MP</given-names></name></person-group><article-title>The molecular basis for public T-cell responses?</article-title><source>Nat Rev Immunol</source><year>2008</year><volume>8</volume><fpage>231</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nri2260</pub-id><?supplied-pmid 18301425?><pub-id pub-id-type="pmid">18301425</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luoma</surname><given-names>AM</given-names></name><name><surname>Castro</surname><given-names>CD</given-names></name><name><surname>Mayassi</surname><given-names>T</given-names></name><name><surname>Bembinster</surname><given-names>LA</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Crystal structure of Vdelta1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human gammadelta T cells</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>1032</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.11.001</pub-id><?supplied-pmid 24239091?><pub-id pub-id-type="pmid">24239091</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uldrich</surname><given-names>AP</given-names></name><name><surname>Le Nours</surname><given-names>J</given-names></name><name><surname>Pellicci</surname><given-names>DG</given-names></name><name><surname>Gherardin</surname><given-names>NA</given-names></name><name><surname>McPherson</surname><given-names>KG</given-names></name><etal/></person-group><article-title>CD1d-lipid antigen recognition by the gammadelta TCR</article-title><source>Nat Immunol</source><year>2013</year><volume>14</volume><fpage>1137</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/ni.2713</pub-id><?supplied-pmid 24076636?><pub-id pub-id-type="pmid">24076636</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Pizarro</surname><given-names>JC</given-names></name><name><surname>Holmes</surname><given-names>MA</given-names></name><name><surname>McBeth</surname><given-names>C</given-names></name><name><surname>Groh</surname><given-names>V</given-names></name><etal/></person-group><article-title>Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>2414</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.1015433108</pub-id><?supplied-pmid 21262824?><pub-id pub-id-type="pmid">21262824</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yacubian</surname><given-names>EM</given-names></name><name><surname>Rosemberg</surname><given-names>S</given-names></name><name><surname>Marie</surname><given-names>SK</given-names></name><name><surname>Valerio</surname><given-names>RM</given-names></name><name><surname>Jorge</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Double pathology in Rasmussen&#x02019;s encephalitis: etiologic considerations</article-title><source>Epilepsia</source><year>1996</year><volume>37</volume><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1996.tb00597.x</pub-id><?supplied-pmid 8617180?><pub-id pub-id-type="pmid">8617180</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>YM</given-names></name><name><surname>Andermann</surname><given-names>F</given-names></name><name><surname>Robitaille</surname><given-names>Y</given-names></name><name><surname>Laxer</surname><given-names>KD</given-names></name><name><surname>Rasmussen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Double pathology in Rasmussen&#x02019;s syndrome: a window on the etiology?</article-title><source>Neurology</source><year>1998</year><volume>50</volume><fpage>731</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1212/WNL.50.3.731</pub-id><?supplied-pmid 9521265?><pub-id pub-id-type="pmid">9521265</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>CA</given-names></name><name><surname>Geyer</surname><given-names>JD</given-names></name><name><surname>Keating</surname><given-names>JM</given-names></name><name><surname>Gilliam</surname><given-names>F</given-names></name><name><surname>Kuzniecky</surname><given-names>RI</given-names></name><etal/></person-group><article-title>Rasmussen&#x02019;s encephalitis with concomitant cortical dysplasia: the role of GluR3</article-title><source>Epilepsia</source><year>1999</year><volume>40</volume><fpage>242</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1999.tb02082.x</pub-id><?supplied-pmid 9952274?><pub-id pub-id-type="pmid">9952274</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>H</given-names></name><name><surname>Wilfong</surname><given-names>A</given-names></name><name><surname>Malphrus</surname><given-names>A</given-names></name><name><surname>Yoshor</surname><given-names>D</given-names></name><name><surname>Hunter</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Dual pathology in Rasmussen&#x02019;s encephalitis: a study of seven cases and review of the literature</article-title><source>Neuropathology</source><year>2010</year><volume>30</volume><fpage>381</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1789.2009.01079.x</pub-id><?supplied-pmid 20051019?><pub-id pub-id-type="pmid">20051019</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prayson</surname><given-names>RA</given-names></name></person-group><article-title>Dual pathology in Rasmussen&#x02019;s encephalitis: a report of coexistent focal cortical dysplasia and review of the literature</article-title><source>Case Rep Pathol</source><year>2012</year><volume>2012</volume><fpage>569170</fpage><?supplied-pmid 23056977?><pub-id pub-id-type="pmid">23056977</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Rourke</surname><given-names>DJ</given-names></name><name><surname>Bergin</surname><given-names>A</given-names></name><name><surname>Rotenberg</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><name><surname>Gorman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rasmussen&#x02019;s encephalitis presenting as focal cortical dysplasia</article-title><source>Epilepsy Behav Case Rep</source><year>2014</year><volume>2</volume><fpage>86</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ebcr.2014.01.009</pub-id><?supplied-pmid 25667877?><pub-id pub-id-type="pmid">25667877</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vezzani</surname><given-names>A</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name><name><surname>Mazarati</surname><given-names>A</given-names></name><name><surname>Pittman</surname><given-names>QJ</given-names></name></person-group><article-title>Epilepsy and brain inflammation</article-title><source>Exp Neurol</source><year>2013</year><volume>244</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2011.09.033</pub-id><?supplied-pmid 21985866?><pub-id pub-id-type="pmid">21985866</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyel</surname><given-names>PA</given-names></name></person-group><article-title>How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1</article-title><source>Cytokine</source><year>2014</year><volume>69</volume><fpage>136</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2014.03.007</pub-id><?supplied-pmid 24746243?><pub-id pub-id-type="pmid">24746243</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>V</given-names></name><name><surname>Walsh</surname><given-names>JG</given-names></name><name><surname>Sinclair</surname><given-names>DB</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Tang-Wai</surname><given-names>R</given-names></name><etal/></person-group><article-title>Inflammasome induction in Rasmussen&#x02019;s encephalitis: cortical and associated white matter pathogenesis</article-title><source>J Neuroinflammation</source><year>2013</year><volume>10</volume><fpage>152</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-10-152</pub-id><?supplied-pmid 24330827?><pub-id pub-id-type="pmid">24330827</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>CE</given-names></name><name><surname>Mielke</surname><given-names>LA</given-names></name><name><surname>Mills</surname><given-names>KH</given-names></name></person-group><article-title>IL-17-producing gammadelta T cells and innate lymphoid cells</article-title><source>Eur J Immunol</source><year>2012</year><volume>42</volume><fpage>2221</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/eji.201242569</pub-id><?supplied-pmid 22949320?><pub-id pub-id-type="pmid">22949320</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blink</surname><given-names>SE</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name></person-group><article-title>The contribution of gammadelta T cells to the pathogenesis of EAE and MS</article-title><source>Curr Mol Med</source><year>2009</year><volume>9</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.2174/156652409787314516</pub-id><?supplied-pmid 19199938?><pub-id pub-id-type="pmid">19199938</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Fleming</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group><article-title>Dermal gammadelta T cells&#x02014;a new player in the pathogenesis of psoriasis</article-title><source>Int Immunopharmacol</source><year>2013</year><volume>16</volume><fpage>388</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2013.02.018</pub-id><?supplied-pmid 23499509?><pub-id pub-id-type="pmid">23499509</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>I</given-names></name><name><surname>Silva-Santos</surname><given-names>B</given-names></name><name><surname>Pennington</surname><given-names>DJ</given-names></name></person-group><article-title>Functional development of gammadelta T cells</article-title><source>Eur J Immunol</source><year>2013</year><volume>43</volume><fpage>1988</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/eji.201343759</pub-id><?supplied-pmid 23928962?><pub-id pub-id-type="pmid">23928962</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribot</surname><given-names>JC</given-names></name><name><surname>Silva-Santos</surname><given-names>B</given-names></name></person-group><article-title>Differentiation and activation of gammadelta T Lymphocytes: focus on CD27 and CD28 costimulatory receptors</article-title><source>Adv Exp Med Biol</source><year>2013</year><volume>785</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1007/978-1-4614-6217-0_11</pub-id><?supplied-pmid 23456842?><pub-id pub-id-type="pmid">23456842</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenborn</surname><given-names>JR</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name></person-group><article-title>Regulation of interferon-gamma during innate and adaptive immune responses</article-title><source>Adv Immunol</source><year>2007</year><volume>96</volume><fpage>41</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/S0065-2776(07)96002-2</pub-id><?supplied-pmid 17981204?><pub-id pub-id-type="pmid">17981204</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>H</given-names></name><name><surname>Cavalie</surname><given-names>A</given-names></name><name><surname>Jenne</surname><given-names>DE</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name></person-group><article-title>Induction of MHC class I genes in neurons</article-title><source>Science</source><year>1995</year><volume>269</volume><fpage>549</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1126/science.7624779</pub-id><?supplied-pmid 7624779?><pub-id pub-id-type="pmid">7624779</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>CA</given-names></name><name><surname>Nabbout</surname><given-names>R</given-names></name><name><surname>Galanopoulou</surname><given-names>AS</given-names></name></person-group><article-title>Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES)</article-title><source>Neurotherapeutics</source><year>2014</year><volume>11</volume><fpage>297</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1007/s13311-014-0265-2</pub-id><?supplied-pmid 24639375?><pub-id pub-id-type="pmid">24639375</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLachlan</surname><given-names>RS</given-names></name><name><surname>Levin</surname><given-names>S</given-names></name><name><surname>Blume</surname><given-names>WT</given-names></name></person-group><article-title>Treatment of Rasmussen&#x02019;s syndrome with ganciclovir</article-title><source>Neurology</source><year>1996</year><volume>47</volume><fpage>925</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/WNL.47.4.925</pub-id><?supplied-pmid 8857720?><pub-id pub-id-type="pmid">8857720</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AM</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name></person-group><article-title>Epitope spreading: protection from pathogens, but propagation of autoimmunity?</article-title><source>Clin Exp Dermatol</source><year>2001</year><volume>26</volume><fpage>427</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2230.2001.00852.x</pub-id><?supplied-pmid 11488833?><pub-id pub-id-type="pmid">11488833</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderlugt</surname><given-names>CL</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name></person-group><article-title>Epitope spreading in immune-mediated diseases: implications for immunotherapy</article-title><source>Nat Rev Immunol</source><year>2002</year><volume>2</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/nri724</pub-id><?supplied-pmid 11910899?><pub-id pub-id-type="pmid">11910899</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chastain</surname><given-names>EM</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name></person-group><article-title>Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease</article-title><source>Immunol Rev</source><year>2012</year><volume>245</volume><fpage>227</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01076.x</pub-id><?supplied-pmid 22168423?><pub-id pub-id-type="pmid">22168423</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusick</surname><given-names>MF</given-names></name><name><surname>Libbey</surname><given-names>JE</given-names></name><name><surname>Fujinami</surname><given-names>RS</given-names></name></person-group><article-title>Molecular mimicry as a mechanism of autoimmune disease</article-title><source>Clin Rev Allergy Immunol</source><year>2012</year><volume>42</volume><fpage>102</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s12016-011-8294-7</pub-id><?supplied-pmid 22095454?><pub-id pub-id-type="pmid">22095454</pub-id></element-citation></ref></ref-list></back></article>